Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Bristol-Myers Squibb, NYSE
Bristol-Myers Squibb (NYSE:BMY) Position Increased by Legacy Private Trust Co.
Legacy Private Trust Co. lifted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC).
Should Bristol-Myers Squibb Company (NYSE:BMY) Be In Your Early Retirement Portfolio?
We recently compiled a list of the Early Retirement Portfolio: 10 Stocks to Live Off Dividends. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other stocks.
Bristol Myers Squibb Co. stock rises Monday, still underperforms market
Bristol Myers Squibb Co. closed $4.40 below its 52-week high ($61.08), which the company achieved on November 11th.
Bristol-Myers Squibb Co (BMY) Stock: Greater Than Its Current Valuation?
Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the stock to Neutral,
Truist Financial Remains a Buy on Bristol-Myers Squibb (BMY)
In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bristol-Myers Squibb's whale activity within a strike price range from $43.0 to $75.0 in the last 30 days.
Bristol-Myers Squibb's (NYSE:BMY) investors will be pleased with their 2.4% return over the last five years
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js
J.M. Smucker Co. stock falls Tuesday, underperforms market
Shares of J.M. Smucker Co. SJM slipped 1.55% to $107.47 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 1.11% to 5,909.03 and Dow Jones Industrial Average DJIA falling 0.
19h
Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day
The stock's fall snapped a two-day winning streak.
1d
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...
1d
Bristol Myers price target raised to $65 from $62 at Truist
Truist raised the firm’s price target on Bristol Myers (BMY) to $65 from $62 and keeps a Buy rating on the shares as part of a broader research ...
FiercePharma
7d
Bristol Myers celebrates 10 years of Opdivo with FDA approval for subcutaneous version
Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...
Yahoo Finance
2d
Bristol-Myers Squibb Company (BMY)
In this article, we are going to take a look at where
Bristol-Myers Squibb Company
(NYSE:BMY) stands against the other stocks. As retirement approaches, ensuring financial stability becomes ...
2d
on MSN
Bristol Myers to report Q4 IPRD/licensing expense of $18M
Bristol Myers Squibb (NYSE:BMY) said it expects to report a Q4 net expense of $18M related to acquired IPRD and licensing ...
Baylor College of Medicine
3d
Baylor College of Medicine
Texas Children’s Global HOPE and Baylor College of Medicine Global Health, with support from the Bristol Myers Squibb ...
5d
on MSN
3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade
Medtronic has been raising its dividend for 47 consecutive years and it offers a high yield now. Bristol Myers Squibb offers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
New York Stock Exchange
BMY
Opdivo
Nivolumab
Feedback